News & Press Releases

Forbes featured insights from Of Counsel Michelle Capezza in an article about the distinction between risk capacity and risk tolerance in retirement planning. The article notes that while many retirement plan participants intuitively understand the concept of risk capacity, its nuances are not always reflected in 401(k) plans.

Business Law Today highlighted comments from Privacy & Cybersecurity Practice Co-chair Scott Lashway, who spoke on a panel at the American Bar Association Business Law Fall Meeting in September. Discussing the role of intellectual property in business transactions, the panel addressed important considerations for the various types of IP, distinguishing the less concrete “lowercase ip” from the more formalized “uppercase IP.”

Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $157.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 318,470 shares of common stock at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to Praxis Precision Medicines from this offering were approximately $603 million before deducting underwriting discounts and commissions and other offering expenses.

Of Counsel Michelle Capezza shared comments with Fiduciary News about how 401k fiduciaries can implement risk capacity, including the importance of providing retirement plan participants with balanced educational materials.

Mintz advised the placement agents in connection with Spruce Biosciences, Inc.'s $50 million private placement.  The investors purchased common stock (and pre-funded warrants in lieu of common stock for certain investors).

Bloomberg Law quoted Joanne Hawana in a recent article about the FDA’s crackdown on potentially misleading drug advertisements following its investigation into the use of social media influencers to promote certain drugs. Attorneys and the telehealth companies they counsel explain in the article that clarity from the FDA is needed on who is responsible for influencer ad messaging, particularly when promoting compounded drugs.